Skip to main content

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET.

A live audio webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.09
+3.14 (1.44%)
AAPL  259.58
+1.13 (0.44%)
AMD  234.99
+4.76 (2.07%)
BAC  51.76
+0.66 (1.29%)
GOOG  253.73
+1.20 (0.48%)
META  734.00
+0.59 (0.08%)
MSFT  520.56
+0.02 (0.00%)
NVDA  182.16
+1.88 (1.04%)
ORCL  280.07
+7.41 (2.72%)
TSLA  448.98
+10.01 (2.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.